NasdaqGS:AMGNBiotechs
Amgen’s Repatha Data Reinforces Cardiovascular Franchise And Valuation Debate
Amgen (NasdaqGS:AMGN) released new VESALIUS-CV Phase 3 subgroup data on Repatha showing a significant reduction in first major cardiovascular events in high risk patients with diabetes.
The results indicate that Repatha, used alongside statins or other LDL C lowering therapies, may support earlier intervention for patients without diagnosed atherosclerosis.
These findings position Repatha as the only PCSK9 inhibitor with evidence across both primary and secondary prevention settings.
For...